


Aleplasinin

Cat. No.:	HY-14759
CAS No.:	481629-87-2
Molecular Formula:	C ₂₈ H ₂₇ NO ₃
Molecular Weight:	425.52
Target:	PAI-1; Amyloid-β
Pathway:	Metabolic Enzyme/Protease; Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (587.52 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.3501 mL	11.7503 mL	23.5007 mL	
5 mM	0.4700 mL	2.3501 mL	4.7001 mL	
10 mM	0.2350 mL	1.1750 mL	2.3501 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research^{[1][2]}.

REFERENCES

[1]. Zhao J, Pei G. Evoking plasmin for beta-amyloid clearance. *Cell Res.* 2008 Aug;18(8):803-4.

[2]. Kellici TF, Pilka ES, Bodkin MJ. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19. *Trends Pharmacol Sci.* 2021 Jun;42(6):431-433.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA